跳至主要内容
临床试验/NCT05679271
NCT05679271招募中不适用

Intracranial Dural Arteriovenous Fistula Related Pulsatile Tinnitus . Endovascular Treatment by Venous Stenting : An Efficacy Study

University Hospital, Bordeaux1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2024年8月22日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
48
试验地点
1
主要终点
Cognard's classification grade

研究概览

简要总结

The goal of this randomized trial to assess the angiographic efficacy of venous stenting in dural arteriovenous fistulae (DAVF) via improvment on Cognard's Classification as compared to no intervention at 6 months Participants belonging to experimental group will be treated using venous stenting. DAVF will be assessed by angiography at 6 months follow-up. Participants belonging to control group will be followed accordingly to standard of care (no treatment). After 6 months, control group patients can be treated by any means accordinlgly to standard of care.

详细描述

DAVF are frequently revealed as a cause of invalidating pulsatile tinnitus (PT). Endovascular treatment (EVT) of DAVF using liquid embolic agent (LEA) is currently performed when an hemorrhagic risk of intracranial hemorrhage is identified (high grade DAVF). PT alone may not be a sufficient condition to offer EVT because procedure-related risks may overcome clinical benefits specifically in case of extended shunts requiring complex procedures. Stenting of dural sinus may represent an alternative to LEA-EVT with a simple and low risk procedure. Thus PT could be cured even in case of low grade DAVF without neurologic risk.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient presenting invalidating pulsatile tinnitus
  • Patient presenting with PT anatomically correlated with a DAVF
  • Type I or IIa DAVF on digital subtraction angiography (DSA), according to Cognard's classification.
  • DAVF located on sigmoid , lateral or posterior longitudinal sinus.
  • Fistula length compatible with use of up to two stents
  • Highly effective contraception for women of childbearing potential, maintained during research procedures
  • Affiliated or beneficiary of health insurance
  • Signed informed consent

排除标准

  • Patient with DAVF not eligible for endovascular treatment .
  • DAVF classification of IIb or more according to Cognard's classification.
  • DAVF with severe sinus stenosis or occlusion judged as nor eligible for sinus stenting.
  • DAVF showing evidence of recent (inferior to 3 months) thrombophlebitis at the site of fistulous dural sinus.
  • Patient with DAVF previously treated with surgery or radiotherapy.
  • Patient with multiple DAVF
  • Controlateral sinus aplasia or occlusion
  • Patient presenting contra-indication to the use of LEA according to the instructions For Use.
  • Patient participating in another clinical study evaluating another medical device,
  • Any condition or any situation that would prohibit the patient from coming to the investigational center for the follow-up as recommended by the study protocol at 6 months.
  • Patient with any known allergy to heparin, acetylsalicylic acid, Coumadin , Warfarin or other antiplatelet medications
  • Patient has undergone a surgery including endovascular procedures in the last 30 days prior to the study procedure.
  • Patient has had an Intracranial hemorrhage and/or subarachnoid hemorrhage in the past 30 days prior to the study procedure
  • Known serious sensitivity to radiographic contrast agents.
  • Known sensitivity to nickel, titanium metals, or their alloys
  • Known renal failure as defined by a serum creatinine > 2.5 mg/dl (or 220 μmol/l) or glomerular filtration rate (GFR) <
  • Patient who has a contraindication to MRI or angiography for whatever reason
  • Women who are pregnant, lactating, or who are planning to become pregnant during the anticipated study period
  • Patient unable to understand the nature, risks, significance and implications of the clinical investigation or unwilling to provide written informed consent
  • Patient under legal protection

结局指标

主要结局

Cognard's classification grade

时间窗: Month 6

Cognard's classification status : from type I (Anterograde drainage into venous sinus) to Type V (Drainage into the spinal perimedullary veins)

次要结局

  • THI score(Baseline, Month 6, Month 12, Month 24)
  • Rate of stent thrombosis(Month 6, Month 12, Month 24)
  • Headaches(Baseline, Month 6)
  • modified Rankin Scale(Baseline, Month 6)
  • unsuccessful stent deployment(Baseline)
  • Concentration troubles(Baseline, Month 6, Month 12, Month 24)
  • Sleep troubles(Baseline, Month 6, Month 12, Month 24)
  • Dizziness(Baseline, Month 6, Month 12, Month 24)

研究者

发起方
University Hospital, Bordeaux
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验